Compare MMI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | SPRY |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 969.2M |
| IPO Year | 2013 | 2020 |
| Metric | MMI | SPRY |
|---|---|---|
| Price | $29.15 | $9.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $28.00 | ★ $40.00 |
| AVG Volume (30 Days) | 211.4K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 84.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $719,700,000.00 | $84,278,000.00 |
| Revenue This Year | $14.04 | $87.40 |
| Revenue Next Year | $11.35 | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.43 | $6.66 |
| 52 Week High | $33.62 | $18.63 |
| Indicator | MMI | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 56.70 |
| Support Level | $27.47 | $9.50 |
| Resistance Level | $31.03 | $9.63 |
| Average True Range (ATR) | 0.92 | 0.57 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 41.07 | 60.54 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.